ASX Announcement 28 October 2016
Trading Update
Our results in FY16 were the beginning of what we see as significant sales growth for our company. Earlier in FY17 we received our first order to deliver product for the French market. That order was the single biggest order our company has ever received.
Revenue overall is growing strongly and is forecast as at the end of October 2016 to be 50% above the same period last year. Revenue from Penthrox is 37% greater than this time last year (October 2015) and we expect H1FY17 sales to show strong growth.
Our respiratory business continues to show strong growth. Global sales are 137% up on the same time last year. Our European business is showing excellent growth (sales up 269%) and we continue to build our infrastructure in North America, which should make a strong contribution in H2FY17.
Bolding added by me.
Most Valuable Player 2017, page-52
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
-0.020(4.30%) |
Mkt cap ! $50.41M | |||
| Open | High | Low | Value | Volume |
| 45.5¢ | 45.5¢ | 44.3¢ | $28.68K | 63.71K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49617 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 2106 | 4 |
View Market Depth
| Last trade - 15.27pm 07/11/2024 (20 minute delay) ? |
| MVP (ASX) Chart |